Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T01:12:30.324Z Has data issue: false hasContentIssue false

Thyroid lymphoma: acute presentation and long-term outcome

Published online by Cambridge University Press:  11 August 2011

S E Penney*
Affiliation:
University Department of Otolaryngology – Head and Neck Surgery, Manchester Royal Infirmary, Manchester, UK
J J Homer
Affiliation:
University Department of Otolaryngology – Head and Neck Surgery, Manchester Royal Infirmary, Manchester, UK Department of Head and Neck Surgery, Christie Hospital, Manchester, UK
*
Address for correspondence: Miss Susannah Penney, University Dept of Otolaryngology – Head and Neck Surgery, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK Fax: +44 (0)161 276 5003 E-mail: [email protected]

Abstract

Background:

Thyroid lymphomas are relatively uncommon. This study aimed to analyse our experience of thyroid lymphoma management and outcome.

Materials and methods:

A retrospective case note analysis of 63 patients treated in the previous 13 years was conducted.

Results:

The five-year survival rate was 68 per cent, with most patients dying of their lymphoma. This is at odds with the British Thyroid Association statement that the prognosis of this condition is ‘generally excellent’. The only presenting symptom found to be significantly associated with prognosis was dysphagia (p = 0.001). Dual modality treatment provided a significantly better outcome than single modality treatment (p = 0.014). Thyroid lymphoma can present to the head and neck surgeon ‘in extremis’; however, it can respond rapidly to appropriate treatment.

Conclusion:

The outcome of thyroid lymphoma seems unrelated to the acuteness of its presentation. Thyroid surgery has no role other than for diagnosis. However, 51 per cent of the study patients underwent some form of thyroidectomy, indicating the need to implement better diagnostic pathways.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Weetman, AP. Endocrine disorders – Thyroid cancer. In: Warell, DA, Cox, TM, Firth, JD, Benz, EJ, eds. Oxford Textbook of Medicine. Oxford: Oxford University Press, 2003;4th Edition, volume 3, pages 225230Google Scholar
2Widder, S, Pasieka, JL. Primary thyroid lymphomas. Curr Treat Options Oncol 2004;5:307–13CrossRefGoogle ScholarPubMed
3Pasieka, JL. Hashimoto's disease and thyroid lymphoma: role of the surgeon. World J Surg 2000;24:966–70CrossRefGoogle ScholarPubMed
4Scholefield, JH, Quayle, AR, Harris, SC, Talbot, CH. Primary lymphoma of the thyroid, the association with Hashimoto's thyroiditis. Eur J Surg Oncol 1992;18:8992Google ScholarPubMed
5DiBase, SJ, Grigsby, PW, Guo, C, Lin, HS, Wasserman, TH. Outcome analysis for stage IE and IIE thyroid lymphoma. Am J Clin Oncol 2004;27:178–84CrossRefGoogle Scholar
6Ansell, SM, Grant, CS, Habermann, TM. Primary thyroid lymphoma. Semin Oncol 1999;26:316–23Google ScholarPubMed
7Belal, AA, Allam, A, Kandil, A, El Husseiny, G, Khafaga, Y, Al Rajhi, N et al. Primary thyroid lymphoma. A retrospective analysis of prognostic factors and treatment outcome for localised intermediate and high-grade lymphoma. Am J Clin Oncol 2001;24:299305CrossRefGoogle ScholarPubMed
8Logue, JP, Hale, RJ, Stewart, AL, Duthie, MB, Banerjee, SS. Primary malignant lymphoma of the thyroid: a clinicopathological analysis. Int J Radiat Oncol Biol Phys 1992;22:929–33CrossRefGoogle ScholarPubMed
9British Thyroid Association, Royal College of Physicians. Guidelines for the management of thyroid cancer (Perros, P, ed) 2nd edition. Report of the Thyroid Cancer Guidelines Update Group. London: Royal College of Physicians, 2007Google ScholarPubMed
10Matsuzuka, F, Miyauchi, A, Katayama, S, Narabayashi, I, Ikeda, H, Kuma, K et al. Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid 1993;3:93–9CrossRefGoogle ScholarPubMed
11Laing, RW, Hoskin, P, Vaughan Hudson, B, Vaughan Hudson, G, Harmer, C, Bennett, MH et al. The significance of MALT histology in thyroid lymphoma: a review of patients from the BNLI and Royal Marsden Hospital. Clin Oncol 1994;6:300–4CrossRefGoogle ScholarPubMed
12Holm, L, Blomgren, H, Lowhagen, T. Cancer risks in patients with chronic lymphocytic thyroiditis. New Eng J Med 1985;312:601–4CrossRefGoogle ScholarPubMed
13Sippel, RS, Gauger, PG, Angelos, P, Thompson, NW, Mack, E, Chen, H. Palliative thyroidectomy for malignant lymphoma of the thyroid. Ann Surg Oncol 2002;9:907–11CrossRefGoogle ScholarPubMed
14Cvetkovic, RS, Perry, CM. Spotlight on rituximab in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. BioDrugs 2006;20:253–7CrossRefGoogle Scholar
15Doria, R, Jekel, JF, Cooper, DL. Thyroid lymphoma: the case for combined modality therapy. Cancer 1994;73:200–63.0.CO;2-#>CrossRefGoogle ScholarPubMed